OKYO Pharma Ltd Reports H1 2024 Financials and Business Update
Ticker: OKYO · Form: 6-K · Filed: Jan 29, 2025 · CIK: 1849296
| Field | Detail |
|---|---|
| Company | Okyo Pharma LTD (OKYO) |
| Form Type | 6-K |
| Filed Date | Jan 29, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, business-update, form-6k
TL;DR
OKYO Pharma dropped H1 2024 results Jan 29, 2025. Check financials & biz updates.
AI Summary
OKYO Pharma Ltd announced its financial results for the six-month period ending September 30, 2024, on January 29, 2025. The company, headquartered in London, also provided an update on its recent business highlights. This filing is a Form 6-K report.
Why It Matters
This filing provides investors with a snapshot of OKYO Pharma's financial performance and strategic progress during the first half of its fiscal year.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing (6-K) and does not contain new material events or significant financial changes.
Key Numbers
- H1 2024 — Reporting Period (Financial results for the six-month period ending September 30, 2024.)
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- January 29, 2025 (date) — Filing Date
- September 30, 2024 (date) — Reporting Period End Date
- London (location) — Company Headquarters
FAQ
What specific financial results were reported for the six-month period ended September 30, 2024?
The filing states that financial results for the six-month period ended September 30, 2024, were reported, but the specific figures are not detailed within this Form 6-K document itself, which refers to an attached press release (Exhibit 99.1).
What are the key business highlights mentioned in the update?
The filing indicates a business update was provided, but the specific details of these highlights are not included in the Form 6-K text and are likely within the referenced Exhibit 99.1.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on January 29, 2025.
What is the principal executive office address for OKYO Pharma Ltd?
The principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
Does OKYO Pharma Ltd file annual reports under Form 20-F or Form 40-F?
OKYO Pharma Ltd indicates it files annual reports under Form 20-F.
Filing Stats: 394 words · 2 min read · ~1 pages · Grade level 12.3 · Accepted 2025-01-29 16:30:21
Filing Documents
- form6-k.htm (6-K) — 23KB
- ex99-1.htm (EX-99.1) — 20KB
- ex99-2.htm (EX-99.2) — 805KB
- ex99-1_001.jpg (GRAPHIC) — 89KB
- ex99-2_001.jpg (GRAPHIC) — 31KB
- 0001493152-25-004156.txt ( ) — 1014KB
financial statements for the six-month period ended September 30, 2024
financial statements for the six-month period ended September 30, 2024. The Announcement is furnished herewith as Exhibit 99.1 and Exhibit 99.2 to this Report on Form 6-K. The information in the attached Exhibits 99.1 and 99.2 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: January 29, 2025 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated January 29, 2025 99.2 Consolidated financial statements for the six-month period ended September 30, 2024 4